Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 9;11(9):2676.
doi: 10.3390/jcm11092676.

COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)

Aleksandra Kubas  1 , Ewa Malecka-Wojciesko  1
Affiliations
Review

COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)

Aleksandra Kubas et al. J Clin Med. .

Abstract

Vaccines against SARS-CoV-2 are believed to play a key role in the suppression of the COVID-19 pandemic. However, patients suffering from inflammatory bowel diseases (IBD) were excluded from SARS-CoV-2 vaccines trials. Therefore, concerns regarding vaccination efficacy and safety among those patients were raised. Overall, vaccination is well tolerated in the IBD population, and different gastroenterological societies recommend vaccinating patients with IBD at the earliest opportunity to do so. Nevertheless, very little is known about the safety of COVID-19 vaccines in special IBD populations such as pregnant and breastfeeding women or pediatric patients, and further research on this matter is crucial. The available data on vaccine efficacy are promising and show high seroconversion rates in IBD patients on different immune-modifying therapies. However, patients treated with high doses of systemic corticosteroids, infliximab or infliximab and immunomodulators may have a blunted response to the vaccination. The data on COVID-19 vaccination willingness among patients with IBD are conflicting. Nevertheless, vaccine effectiveness and safety are reported to be the most common reasons for hesitancy. This review examines the effectiveness and safety of COVID-19 vaccines and describes vaccination willingness and the reasons for potential hesitancy among patients with IBD.

Keywords: COVID-19 vaccination; biologic therapy; inflammatory bowel disease; vaccination willingness; vaccine effectiveness; vaccine safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Prentice R.E., Rentsch C., Al-Ani A.H., Zhang E., Johnson D., Halliday J., Bryant R., Begun J., Ward M.G., Lewindon P.J., et al. SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease. GastroHep. 2021;3:212–228. doi: 10.1002/ygh2.473. - DOI - PMC - PubMed
    1. Rahier J.F., Magro F., Abreu C., Armuzzi A., Ben-Horin S., Chowers Y., Cottone M., de Ridder L., Doherty G., Ehehalt R., et al. Second European Evidence-Based Consensus on the Prevention, Diagnosis and Management of Opportunistic Infections in Inflammatory Bowel Disease. J. Crohn’s Colitis. 2014;8:443–468. doi: 10.1016/j.crohns.2013.12.013. - DOI - PubMed
    1. Al-Ani A.H., Prentice R.E., Rentsch C.A., Johnson D., Ardalan Z., Heerasing N., Garg M., Campbell S., Sasadeusz J., Macrae F.A., et al. Review Article: Prevention, Diagnosis and Management of COVID-19 in the IBD Patient. Aliment Pharmacol. Ther. 2020;52:54–72. doi: 10.1111/apt.15779. - DOI - PMC - PubMed
    1. Aziz M., Fatima R., Haghbin H., Lee-Smith W., Nawras A. The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-Analysis. Inflamm. Bowel Dis. 2020;26:e132–e133. doi: 10.1093/ibd/izaa170. - DOI - PMC - PubMed
    1. Allocca M., Fiorino G., Zallot C., Furfaro F., Gilardi D., Radice S., Danese S., Peyrin-Biroulet L. Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients from the Nancy and Milan Cohorts. Clin. Gastroenterol. Hepatol. 2020;18:2134–2135. doi: 10.1016/j.cgh.2020.04.071. - DOI - PMC - PubMed

LinkOut - more resources